Developer docs
API playgroundTry for free, no card

Search company profiles

Beta Bionics

Full company profile

uuid000046p

Namestring
Beta Bionics
Legal namestring
Beta Bionics, Inc.
Websiteurl
betabionics.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Beta Bionics is a commercial-stage medical technology company that develops and markets the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system for people with type 1 diabetes aged six and older. The iLet integrates the iLet ACE Pump, proprietary iLet Dosing Decision Software, and continuous glucose monitor data (Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus) into a closed-loop platform that autonomously makes 100% of insulin dosing decisions through an adaptive algorithm requiring only patient weight to initiate therapy. The system was FDA-cleared in May 2023 and commercially launched in December 2023, with the Color iLet variant introduced in 2024 adding a color display, louder alerts, and expanded CGM interoperability.

The company's business model blends one-time hardware revenue from the iLet device with a high-margin recurring consumables stream (insulin cartridges and infusion sets) and a software/data layer that includes the Bionic Circle remote-monitoring app, Bionic Insights for clinicians, and a public Real-World Data Dashboard. Distribution runs through both Durable Medical Equipment (DME) providers and a Pharmacy Benefit (PBP) channel where patient out-of-pocket costs are approximately $25 per month versus $500 to $1,500 under DME; the PBP channel is now projected to account for 36–39% of new patient starts in 2026. Commercial motion combines an enterprise field sales force targeting endocrinologists (with 20+ new territories added in Q1 2026), certified trainer programs, HCP webinars, the Bionic Universe patient community, and a direct-to-patient Pharmacy Advantage Program offering $0 to start with the first 30 days free.

Beta Bionics is publicly traded on NASDAQ under ticker BBNX, headquartered in Irvine, California with operations in Massachusetts, and was founded in 2015. The company has raised over $282 million in venture funding across Series C ($57M, 2022), Series D ($100M, 2023), and Series E ($60M, 2024) rounds, and reports a net cash position of approximately $240 million. Full-year 2025 net sales were $100.3 million, up 54% year-over-year on an installed base that roughly doubled to 35,000 users, and 2026 revenue is guided to $131–136 million. The product roadmap extends to the Mint semi-durable patch pump targeted for full launch by end of Q2 2027 and a bihormonal system in development.

Short descriptiontext

Beta Bionics is a commercial-stage medical technology company that develops and sells the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system using adaptive algorithms for type 1 diabetes patients aged six and older in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersIrvine, United States
HQ citystring
Irvine
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
automated insulin delivery, bionic pancreas systems, diabetes management devices, continuous glucose monitoring, insulin pump therapy
Industry3 codes
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKADAA
Diabetes (General)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Automated Insulin Delivery Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1iLet Device Sales
TypeHardware Sales
Description

Sales of the iLet Bionic Pancreas hardware device to patients through DME and pharmacy channels, representing initial customer acquisition revenue.

finance.yahoo.com
2Recurring Supply Revenue
TypeSubscription Recurring
Description

Recurring revenue from insulin cartridges, infusion sets, and other consumables. As the pharmacy installed base crossed the accretion threshold, high-margin recurring supply revenue has become a primary profit driver. Q1 2026 gross margin expanded to 59.5%, up 864 basis points year-over-year.

finance.yahoo.com
3Pharmacy Channel Revenue
TypeHardware Sales
Description

Revenue through pharmacy benefit with significantly lower patient out-of-pocket costs (~$25/month) compared to DME reimbursement ($500-$1,500), driving volume growth in new patient starts with high-30s percentage of new starts now coming through pharmacy.

seekingalpha.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
Pricing details2 tiers
1Pharmacy Advantage Program - $0 to Start
ModelSubscriptionBilling cadenceMonthly
Notes

First 30 days completely free with no hardware lock-in and no upfront cost. Monthly cost approximately $25 through pharmacy benefit versus $500-$1,500 under DME reimbursement.

betabionics.com
24-Year Device Warranty
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

iLet Bionic Pancreas device warranty valid for 4 years from original date of shipment. Warranty covers defects in materials and workmanship under normal use.

betabionics.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1iLet Bionic Pancreas
Description

Automated insulin delivery system that reduces the need for manual diabetes management decisions by making 100% of insulin dosing decisions automatically.

betabionics.com
+2 more records
Core offering1 text field

Beta Bionics develops and sells the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system consisting of the iLet ACE Pump paired with the iLet Dosing Decision Software. The system integrates with Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus continuous glucose monitors and uses a proprietary adaptive algorithm to autonomously determine 100% of insulin doses for people with type 1 diabetes aged six and older. Revenue is generated from hardware device sales plus high-margin recurring revenue from consumable insulin cartridges and infusion sets, distributed through Pharmacy Benefit and Durable Medical Equipment reimbursement channels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Average HbA1c reduction from 9.0% to 7.4% (1.6% improvement) across real-world patient population
+4 more records
Product overview1 text field

Beta Bionics is a commercial-stage medical technology company offering the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system for type 1 diabetes. The core product consists of the iLet ACE Pump hardware, iLet Dosing Decision Software, and compatible continuous glucose monitors (Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus). The system is distinguished by its adaptive autonomous algorithm that requires only patient weight to initiate therapy and makes 100% of dosing decisions. Companion products include the Bionic Circle App for remote monitoring, iLet Mobile App for device control, Bionic Insights for clinical decision support, and the Pharmacy Advantage Program for acquisition. The company is developing the Mint semi-durable patch pump and a bihormonal system.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-12
Description

Dexcom is a critical technology partner providing CGM integration for the iLet Bionic Pancreas. The system is compatible with Dexcom G6 and G7 sensors, enabling automated insulin dosing based on continuous glucose readings. Beta Bionics announced iLet integration with Dexcom G7 15-day sensor.

2Abbott Laboratories
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-05-19
Description

Abbott is a technology partner providing FreeStyle Libre 3 Plus CGM sensor integration for the iLet Bionic Pancreas. Beta Bionics announced launch of iLet with Abbott's FreeStyle Libre 3 Plus sensor, making iLet the only AID system compatible with both Dexcom and Abbott CGMs.

betabionics.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-18
Description

Novo Nordisk participated as a clinical trial partner and investor in Beta Bionics' artificial pancreas development, including in the Series C funding and pivotal trials for the iLet device.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-18
Description

Eli Lilly participated as a clinical trial partner and investor in Beta Bionics' artificial pancreas development, including in the Series C funding and pivotal trials for the iLet device.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-02-18
Description

Zealand Pharma participated as a clinical trial partner and investor in Beta Bionics' artificial pancreas development, including in the Series C funding and pivotal trials for the iLet device.

Strategic tierCoreTypeTechnology or Integration
Description

Convatec supplies infusion sets (Inset and Contact Detach) for use with the iLet Bionic Pancreas. Both 6mm cannula length variants are available as compatible infusion sets for iLet users.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct AID competitor with the t:slim X2 insulin pump and Control-IQ algorithm, serving the same Type 1 diabetes patient population with a comparable closed-loop system integrated with Dexcom CGMs.

TypeDirect peer
Description

Direct AID competitor offering the Omnipod 5 tubeless patch pump with SmartAdjust algorithm, competing head-to-head with iLet for Type 1 diabetes patients and pharmacy benefit reimbursement.

TypeDirect peer
Description

Direct AID competitor with the MiniMed 780G closed-loop system; broader incumbent with larger installed base, established payer relationships, and integrated CGM (Guardian 4).

TypeBroad incumbent
Description

Core CGM technology partner to Beta Bionics (Dexcom G6/G7) and adjacent competitor pursuing its own AID partnerships; comparable in the broader automated glucose management ecosystem and a key dependency for iLet dosing.

TypeBroad incumbent
Description

FreeStyle Libre 3 Plus CGM partner to Beta Bionics and adjacent incumbent in diabetes technology; acquired Bigfoot Biomedical in 2023, signaling strategic interest in the insulin delivery space.

TypeEmerging player
Description

European emerging AID developer with proprietary self-learning algorithm (DBLG1) integrated with multiple pumps and CGMs; directly comparable technology approach though currently focused on EU markets.

TypeEmerging player
Description

Emerging insulin pump developer (twiiq) targeting Type 2 and Type 1 diabetes with a focus on affordability and simplification; potential future AID competitor with simplified user experience.

TypeEmerging player
Description

Early-stage patch pump developer (MODD1) pursuing FDA 510(k) clearance for a simple, affordable insulin delivery platform targeting the same Type 1 / pump-naive segment Beta Bionics is converting.

TypeBroad incumbent
Description

Broad incumbent in diabetes (Accu-Chek) that previously operated in insulin pumps and now focuses on integrated diabetes management; comparable as a large diabetes player though no longer a direct pump competitor.

TypeEmerging player
Description

UK-based emerging AID developer with the CamAPS FX algorithm used in multiple European pump integrations; comparable closed-loop technology approach with growing clinical evidence base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beta Bionics

Automated Insulin Delivery Devicesbetabionics.com

Beta Bionics is a commercial-stage medical technology company that develops and sells the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system using adaptive algorithms for type 1 diabetes patients aged six and older in the United States.

What Beta Bionics does

Beta Bionics is a commercial-stage medical technology company that develops and markets the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system for people with type 1 diabetes aged six and older. The iLet integrates the iLet ACE Pump, proprietary iLet Dosing Decision Software, and continuous glucose monitor data (Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus) into a closed-loop platform that autonomously makes 100% of insulin dosing decisions through an adaptive algorithm requiring only patient weight to initiate therapy. The system was FDA-cleared in May 2023 and commercially launched in December 2023, with the Color iLet variant introduced in 2024 adding a color display, louder alerts, and expanded CGM interoperability.

The company's business model blends one-time hardware revenue from the iLet device with a high-margin recurring consumables stream (insulin cartridges and infusion sets) and a software/data layer that includes the Bionic Circle remote-monitoring app, Bionic Insights for clinicians, and a public Real-World Data Dashboard. Distribution runs through both Durable Medical Equipment (DME) providers and a Pharmacy Benefit (PBP) channel where patient out-of-pocket costs are approximately $25 per month versus $500 to $1,500 under DME; the PBP channel is now projected to account for 36–39% of new patient starts in 2026. Commercial motion combines an enterprise field sales force targeting endocrinologists (with 20+ new territories added in Q1 2026), certified trainer programs, HCP webinars, the Bionic Universe patient community, and a direct-to-patient Pharmacy Advantage Program offering $0 to start with the first 30 days free.

Beta Bionics is publicly traded on NASDAQ under ticker BBNX, headquartered in Irvine, California with operations in Massachusetts, and was founded in 2015. The company has raised over $282 million in venture funding across Series C ($57M, 2022), Series D ($100M, 2023), and Series E ($60M, 2024) rounds, and reports a net cash position of approximately $240 million. Full-year 2025 net sales were $100.3 million, up 54% year-over-year on an installed base that roughly doubled to 35,000 users, and 2026 revenue is guided to $131–136 million. The product roadmap extends to the Mint semi-durable patch pump targeted for full launch by end of Q2 2027 and a bihormonal system in development.

Beta Bionics firmographics

Firmographics
Name
Beta Bionics
Legal name
Beta Bionics, Inc.
Website
https://betabionics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
251–500 employees
Short description
Beta Bionics is a commercial-stage medical technology company that develops and sells the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system using adaptive algorithms for type 1 diabetes patients aged six and older in the United States.
Ownership category
akta.pro rank

Beta Bionics industry classification

Industry
Product category
Automated Insulin Delivery Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAF
Automated Insulin Delivery (AID) / Closed-Loop Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAG
Insulin Pumps & Patch Pumps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKADAA
Diabetes (General)

Keywords

  • Automated insulin delivery
  • Bionic pancreas systems
  • Diabetes management devices
  • Continuous glucose monitoring
  • Insulin pump therapy

Where Beta Bionics is headquartered

Location

Headquarters

HQ city
Irvine
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Beta Bionics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. iLet Device Sales: Sales of the iLet Bionic Pancreas hardware device to patients through DME and pharmacy channels, representing initial customer acquisition revenue.
  2. Recurring Supply Revenue: Recurring revenue from insulin cartridges, infusion sets, and other consumables. As the pharmacy installed base crossed the accretion threshold, high-margin recurring supply revenue has become a primary profit driver. Q1 2026 gross margin expanded to 59.5%, up 864 basis points year-over-year.
  3. Pharmacy Channel Revenue: Revenue through pharmacy benefit with significantly lower patient out-of-pocket costs (~$25/month) compared to DME reimbursement ($500-$1,500), driving volume growth in new patient starts with high-30s percentage of new starts now coming through pharmacy.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyPharmacy Advantage Program - $0 to Start
One time/ perpetual licenseMulti-year contract4-Year Device Warranty

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Beta Bionics product offering

Product offering

Core offering

Beta Bionics develops and sells the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system consisting of the iLet ACE Pump paired with the iLet Dosing Decision Software. The system integrates with Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus continuous glucose monitors and uses a proprietary adaptive algorithm to autonomously determine 100% of insulin doses for people with type 1 diabetes aged six and older. Revenue is generated from hardware device sales plus high-margin recurring revenue from consumable insulin cartridges and infusion sets, distributed through Pharmacy Benefit and Durable Medical Equipment reimbursement channels.

Product overview

Beta Bionics is a commercial-stage medical technology company offering the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system for type 1 diabetes. The core product consists of the iLet ACE Pump hardware, iLet Dosing Decision Software, and compatible continuous glucose monitors (Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus). The system is distinguished by its adaptive autonomous algorithm that requires only patient weight to initiate therapy and makes 100% of dosing decisions. Companion products include the Bionic Circle App for remote monitoring, iLet Mobile App for device control, Bionic Insights for clinical decision support, and the Pharmacy Advantage Program for acquisition. The company is developing the Mint semi-durable patch pump and a bihormonal system.

Differentiator

Problem solved

Functional benefit

Brands

  • iLet Bionic Pancreas: Automated insulin delivery system that reduces the need for manual diabetes management decisions by making 100% of insulin dosing decisions automatically.
  • Bionic Circle App
  • iLet Mobile App

Quantifiable outcome

  • Average HbA1c reduction from 9.0% to 7.4% (1.6% improvement) across real-world patient population
  • +4 more outcomes

Companies that use Beta Bionics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Beta Bionics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability2 records

Feature5 records

Beta Bionics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • DexcomcoreTechnology or Integration · 12 May 2026Dexcom is a critical technology partner providing CGM integration for the iLet Bionic Pancreas. The system is compatible with Dexcom G6 and G7 sensors, enabling automated insulin dosing based on continuous glucose readings. Beta Bionics announced iLet integration with Dexcom G7 15-day sensor.
  • Abbott LaboratoriescoreTechnology or Integration · 19 May 2023Abbott is a technology partner providing FreeStyle Libre 3 Plus CGM sensor integration for the iLet Bionic Pancreas. Beta Bionics announced launch of iLet with Abbott's FreeStyle Libre 3 Plus sensor, making iLet the only AID system compatible with both Dexcom and Abbott CGMs.
  • Novo NordiskminorStrategic or Co-development Partner · 18 February 2022Novo Nordisk participated as a clinical trial partner and investor in Beta Bionics' artificial pancreas development, including in the Series C funding and pivotal trials for the iLet device.
  • Eli LillyminorStrategic or Co-development Partner · 18 February 2022Eli Lilly participated as a clinical trial partner and investor in Beta Bionics' artificial pancreas development, including in the Series C funding and pivotal trials for the iLet device.
  • Zealand PharmaminorStrategic or Co-development Partner · 18 February 2022Zealand Pharma participated as a clinical trial partner and investor in Beta Bionics' artificial pancreas development, including in the Series C funding and pivotal trials for the iLet device.
  • ConvateccoreTechnology or IntegrationConvatec supplies infusion sets (Inset and Contact Detach) for use with the iLet Bionic Pancreas. Both 6mm cannula length variants are available as compatible infusion sets for iLet users.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

Beta Bionics competitors and assessment

Company assessment

Direct peers

  • Tandem Diabetes Care: Direct AID competitor with the t:slim X2 insulin pump and Control-IQ algorithm, serving the same Type 1 diabetes patient population with a comparable closed-loop system integrated with Dexcom CGMs.
  • Insulet Corporation: Direct AID competitor offering the Omnipod 5 tubeless patch pump with SmartAdjust algorithm, competing head-to-head with iLet for Type 1 diabetes patients and pharmacy benefit reimbursement.
  • Medtronic Diabetes: Direct AID competitor with the MiniMed 780G closed-loop system; broader incumbent with larger installed base, established payer relationships, and integrated CGM (Guardian 4).

Broad incumbents

  • Dexcom: Core CGM technology partner to Beta Bionics (Dexcom G6/G7) and adjacent competitor pursuing its own AID partnerships; comparable in the broader automated glucose management ecosystem and a key dependency for iLet dosing.
  • Abbott Diabetes Care: FreeStyle Libre 3 Plus CGM partner to Beta Bionics and adjacent incumbent in diabetes technology; acquired Bigfoot Biomedical in 2023, signaling strategic interest in the insulin delivery space.
  • Roche Diabetes Care: Broad incumbent in diabetes (Accu-Chek) that previously operated in insulin pumps and now focuses on integrated diabetes management; comparable as a large diabetes player though no longer a direct pump competitor.

Emerging players

  • Diabeloop: European emerging AID developer with proprietary self-learning algorithm (DBLG1) integrated with multiple pumps and CGMs; directly comparable technology approach though currently focused on EU markets.
  • Sequel Med Tech: Emerging insulin pump developer (twiiq) targeting Type 2 and Type 1 diabetes with a focus on affordability and simplification; potential future AID competitor with simplified user experience.
  • Modular Medical: Early-stage patch pump developer (MODD1) pursuing FDA 510(k) clearance for a simple, affordable insulin delivery platform targeting the same Type 1 / pump-naive segment Beta Bionics is converting.
  • CamDiab: UK-based emerging AID developer with the CamAPS FX algorithm used in multiple European pump integrations; comparable closed-loop technology approach with growing clinical evidence base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Beta Bionics social profiles

Digital presence

Beta Bionics compliance and trust

Trust signal

Compliance2 records

Beta Bionics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beta Bionics leadership team

Management profile

Number of profiles

Profiles17 records

Beta Bionics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beta Bionics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beta Bionics

What does Beta Bionics do?

Beta Bionics develops and sells the iLet Bionic Pancreas, an FDA-cleared automated insulin delivery system consisting of the iLet ACE Pump paired with the iLet Dosing Decision Software. The system integrates with Dexcom G6/G7 and Abbott FreeStyle Libre 3 Plus continuous glucose monitors and uses a proprietary adaptive algorithm to autonomously determine 100% of insulin doses for people with type 1 diabetes aged six and older. Revenue is generated from hardware device sales plus high-margin recurring revenue from consumable insulin cartridges and infusion sets, distributed through Pharmacy Benefit and Durable Medical Equipment reimbursement channels.

Is Beta Bionics a public or private company?

Beta Bionics is a public company. It is classified as public and is currently operating.

When was Beta Bionics founded?

Beta Bionics was founded in 2015. It employs 251 to 500 people.

Where is Beta Bionics based?

Beta Bionics is headquartered in Irvine, United States, in the North America region.

How does Beta Bionics make money?

Three revenue lines are on record. iLet Device Sales are the primary driver. The others are recurring Supply Revenue and pharmacy Channel Revenue.

Who are Beta Bionics's main competitors?

Direct peers on record are Tandem Diabetes Care, Insulet Corporation and Medtronic Diabetes. Broad incumbents are Dexcom, Abbott Diabetes Care and Roche Diabetes Care. Emerging players are Diabeloop, Sequel Med Tech, Modular Medical and CamDiab.

Does Beta Bionics have an API?

No public API is recorded for Beta Bionics.

What industry is Beta Bionics in?

Beta Bionics's product category is Automated Insulin Delivery Devices. Its primary akta.pro industry code is HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems, with a secondary code of HLAHAIAG, Insulin Pumps & Patch Pumps. Its NAICS code is 339113 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MedTech DiveSenseonics, Beta Bionics integrate diabetes technologySenseonics and Beta Bionics integrated their glucose sensors and insulin pumps, making Senseonics' Eversense 365 CGM compatible with Beta Bionics' iLet Bionic Pancreas. The partnership aims to reduce diabetes management burden, and Beta Bionics plans a U.S. launch of its Mint patch pump in Q1 2027.YahooSenseonics, Beta Bionics integrate diabetes technologySenseonics and Beta Bionics integrated their glucose sensor and insulin pump, making Senseonics' Eversense 365 CGM compatible with Beta Bionics' iLet Bionic Pancreas. The companies plan to later pair the CGM with Beta Bionics' Mint tubeless patch pump, which received FDA clearance in September.MarketScreenerCertain Restricted Stock Units of Beta Bionics, Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2026.Beta Bionics' restricted stock units are subject to a lock-up agreement ending 15-NOV-2026, covering 61 days from 15-SEP-2026. The company's iLet Bionic Pancreas is an FDA-cleared insulin delivery device for Type 1 diabetes, and it is developing a patch pump and bihormonal configuration.MarketScreenerCertain Options of Beta Bionics, Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2026.Certain options of Beta Bionics, Inc. are subject to a lock-up agreement ending on 15-NOV-2026, covering 61 days from 15-SEP-2026. The company, a diabetes device maker, has an FDA-cleared iLet Bionic Pancreas and is developing a patch pump and bihormonal configuration.Seeking AlphaThese healthcare stocks have tumbled in 2026, yet Quant ratings stay positive (XLV:NYSEARCA)Healthcare stocks including LENSAR, Insulet, and Beta Bionics have fallen 53.05%, 47.29%, and 44.37% in 2026, while Quant ratings remain positive. Village Farms International holds the highest rating at Strong Buy (4.64) with the smallest decline at 22.19%. The article cites regulatory uncertainty, drug-pricing pressures, and reimbursement changes as key factors.Stock TitanSenseonics Q3 revenue up ~140%, 2026 outlook raisedSenseonics reported Q3 2026 revenue of $19.6 million, up about 140% year-over-year, with U.S. revenue of $16.8 million. The company raised its full-year 2026 revenue guidance to $68-70 million and gross margin guidance to over 60%. It also announced a partnership with Beta Bionics for Eversense 365 integration.YahooBeta Bio: 3 Key Takeaways for Long-Term InvestorsBeta Bio reported $35.5 million in net sales for Q3 2026, driven by adoption of its automated insulin delivery platform. The company received FDA clearance for its Mint patch pump, expecting full U.S. commercialization in Q1 2027, and plans to resubmit a 510(k) for its 3D Intelligence dosing algorithm in mid-Q4 2026.NasdaqBeta Bio: 3 Key Takeaways for Long-Term InvestorsBeta Bio reported $35.5 million in third-quarter net sales, driven by adoption of its automated insulin delivery platform. The company raised its full-year 2026 low-end revenue guidance from $121 million to $124 million, with the high end unchanged at $126 million. Management expects FDA clearance for its Mint patch pump to enable full commercial launch in Q1 2027.The Motley FoolBeta Bio: 3 Key Takeaways for Long-Term InvestorsBeta Bio reported $35.5 million in net sales for Q3 2026, driven by adoption of its automated insulin delivery platform. The company received FDA clearance for its Mint patch pump, expecting full U.S. commercialization in Q1 2027, and plans to resubmit its 3D Intelligence 510(k) in mid-Q4 2026.The Motley FoolBeta Bio: 3 Key Takeaways for Long-Term InvestorsBeta Bio reported $35.5 million in net sales for Q3 2026, driven by adoption of its automated insulin delivery platform. The company received FDA clearance for its Mint patch pump, expecting full U.S. commercialization in Q1 2027, and plans to resubmit its 3D Intelligence 510(k) in mid-Q4 2026.